endothelin-1 and 1-((4-5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine

Stroke is the leading cause of adult disability worldwide. The absence of more effective interventions in the chronic stage-that most patients stand to benefit from-reflects uncertainty surrounding mechanisms that govern recovery. The present work investigated the effects of a novel treatment (selective cyclooxygenase-1, COX-1, inhibition) in a model of focal ischemia.. FR122047 (COX-1 inhibitor) was given beginning 7 days following stroke (cortical microinjection of endothelin-1) in 23 adult male rats. Longitudinal continuous-arterial-spin-labeling was performed prior to treatment (7 days), and repeated following treatment (21 days) on a 7T magnetic resonance imaging (MRI) system to estimate resting perfusion and reactivity to hypercapnia. These in vivo measurements were buttressed by immunohistochemistry.. These findings shed light on the role of COX-1 in chronic ischemic injury and suggest that delayed selective COX-1 inhibition exerts multiple beneficial effects on the neurogliovascular unit.. 1 Technical Efficacy: Stage 4 J. MAGN. RESON. IMAGING 2017;46:505-517.

Topics: Animals; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelin-1; Ischemia; Macrophages; Magnetic Resonance Imaging; Male; Membrane Proteins; Microglia; Neuroglia; Neurons; Perfusion; Piperazines; Rats; Rats, Sprague-Dawley; Spin Labels; Stroke; Thiazoles